Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV
By A. Steff, J. Monroe, Kristian Friedrich, S. Chandramouli, Thi Lien-Anh Nguyen, Sai Tian, Sarah Vandepaer, J. Toussaint, A. Carfi. 2017
39 citations recorded by the source corpus.
Human respiratory syncytial virus (hRSV) is responsible for serious lower respiratory tract disease in infants and in older adults, and remains an important vaccine need. RSV fusion (F) glycoprotein is a key target for neutralizing antibodies. RSV F stabilized in its pre-fusion conformation (DS-Cav1 F) induces high neutralizing antibody titers in naïve animals, but it remains unknown to what extent pre-fusion F can boost pre-existing neutralizing responses in RSV seropositive adults. We here assess DS-Cav1 F immunogenicity in seropositive cattle pre-exposed to bovine RSV, a virus closely related to hRSV. A single immunization with non-adjuvanted DS-Cav1 F strongly boosts RSV neutralizing responses, directed towards pre-fusion F-specific epitopes, whereas a post-fusion F is unable to do so. Vaccination with pre-fusion F thus represents a promising strategy for maternal immunization and for other RSV vaccine target populations such as older adults. Boosting of maternal antibodies against RSV is a potential approach to protect infants from severe infection, but data from animal models is missing. Here Steff et al. test two different boosts in seropositive cattle pre-exposed to bovine RSV and show that pre-fusion F strongly boosts neutralizing responses.
Subfields: Epidemiology, Infectious Diseases
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Infectious Diseases
Citations in the corpus
- Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus (2019, background): “…of DS-Cav1, a prefusion-stabilized F antigen that has elicited significantly higher neutralizing antibody titers than postfusion F in naive mice and nonhuman primates (McLellan et al., 2013b) and bovine RSV-primed cattle (Steff et al., 2017) and is now in Phase I clinical trials (NCT03049488).”